Tag: PeptiDream
Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders
TOKYO and KANAGAWA – WEBWIRE – Monday, July 24, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, Astellas) and PeptiDream Inc. (TSE: 4587, President and CEO: Patrick C. Reid, PeptiDream) today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas. Under the agreement between the two companies, Astellas will have the option to select up to three additional targets to be included in the collaboration. Astellas focuses on targeted protein degraders directed to undruggable targets that are difficult to approach with conventional technologies. Under the terms of the ... Read more